U.S. Rep. Jim Sensenbrenner
Press Release

House Approves Conference Report on Comprehensive Opioid Legislation

Deaths from prescription opioids and heroin set a record in 2014, climbing to 28,647.

By - Jul 8th, 2016 11:30 am

Washington, D.C. – Today, the U.S. House of Representatives approved the conference report for a comprehensive legislative package to combat the national opioid epidemic, which is ravaging individuals, families, and communities throughout the country.

Among the eighteen bills passed and considered in the conference committee on the opioid epidemic prior to today’s approval was H.R. 5046, the flagship legislation considered on this issue, which was sponsored by Rep. Jim Sensenbrenner (R-Wis.).

H.R. 5046, the Comprehensive Opioid Abuse Reduction Act (COARA), creates a comprehensive opioid abuse reduction program at the Department of Justice, which would, among other things, provide vital training and resources for first responders and law enforcement, aid in criminal investigations for the unlawful distribution of opioids, expand drug courts, and promote residential substance abuse.

Additionally, the comprehensive grant program created by H.R. 5046 is fully offset, meaning it successfully directs funds to address the opioid epidemic by taking advantage of existing funding. The result is no net increase in spending authorizations and no additional burden on the American taxpayer, which is a responsible, good-government approach to the epidemic.

Congressman Sensenbrenner: “Opioid and heroin abuse is an issue that doesn’t discriminate – it hurts individuals, families, and communities in every corner of this country. Today’s House approval of the conference report is a testimony to the seriousness of legislators to work together, compromise, and find real solutions. It is an important landmark that offers renewed hope for everyone impacted by this devastating epidemic.”

Addiction to opioids such as heroin, morphine, and other prescription pain medicines, has a devastating hold on this country. Between 435,000 and 1.5 million people in the United States currently use heroin, and an alarming number of them are younger than 25 years old.

Deaths from prescription opioids and heroin set a record in 2014, climbing to 28,647. Beyond health care costs, other significant economic burdens are associated with opioid abuse, such as costs related to criminal justice and lost workplace productivity. In total, opioid abuse imposes an estimated $55 billion in societal costs annually.

Press Releases by U.S. Rep. Jim Sensenbrenner

U.S. Rep. Jim Sensenbrenner

Rep. Sensenbrenner Reintroduces the Safe RESEARCH Act to Prohibit the Sale of Fetal Tissue

"This legislation is an important step forward in the ongoing efforts to protect innocent lives and fight on behalf of the unborn."

U.S. Rep. Jim Sensenbrenner

Congressman Sensenbrenner Reintroduces Bill to Stop the Sexual Exploitation of Children

The Adam Walsh Reauthorization Act would allow the protections of the Adam Walsh Protection and Safety Act to continue saving the lives of children throughout the nation.

U.S. Rep. Jim Sensenbrenner

Congressman Sensenbrenner Introduces the Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2017

Functional gastrointestinal and motility disorders affect two in five Americans.

U.S. Rep. Jim Sensenbrenner

Congressman Sensenbrenner Introduces the BUILD WALL Act of 2017

The BUILD WALL Act would use money forfeited from drug traffickers to fund increased border security on the U.S./ Mexican border.

U.S. Rep. Jim Sensenbrenner

For the Second Consecutive Year, Congressman Sensenbrenner Earns Perfect Voting Record

"Each year, I host more than 100 public events, such as town hall meetings and office hours, and respond to thousands of constituent comments submitted by phone, mail, and email."

U.S. Rep. Jim Sensenbrenner

Rep. Sensenbrenner Statement on the Nomination of Judge Neil Gorsuch to the United States Supreme Court

"Judge Gorsuch has proven himself an ardent defender of the Constitution"

See More Releases

Leave a Reply

Your email address will not be published. Required fields are marked *